News

Oxilio Reports Favourable Open-Labelled Clinical Study to Evaluate the Safety and Pharmacokinetic Profile of OXL001 using TRx Technology

Cambridge, UK, 20th June 2023 – TRx Biosciences today announces favourable safety and pharmacokinetic data from a single-part, five-period, sequential, open-labelled Phase 1 study of OXL001, a novel treatment for cancer under development by Oxilio Limited, which leverages TRx’s oral targeted delivery technology. Oxilio has today confirmed that the objectives of the study, conducted at

View Article

Monument Tx to present positive first-in-human clinical study data for MT1980, a novel treatment for neuroinflammation enabled by TRx technology

Cambridge, UK, 28th March 2023 – TRx Biosciences today announces that Monument Therapeutics, a stratified neuroscience company, will be presenting positive results from their lead clinical program, MT1980, at the AD/PD conference, March 28th–April 1st 2023. MT1980 In this presentation, Monument Tx will report data from their first-in-human Phase I study of MT1980, an anti-inflammatory

View Article

TRx Biosciences Announces Completion of Seed Round Fundraise

Cambridge, UK, 12th October 2021 – Funds secured from an esteemed group of private life science specialists allows creation of TRx’s wholly-owned product pipeline.

View Article

TRx signs Out-licensing Agreement with Monument Therapeutics

Cambridge, UK, 19th June 2021 – TRx announces its first technology licensing agreement in Neuroscience with digital biomarker specialist, Monument Therapeutics.

View Article

TRx signs cannabinoid Research Agreement with Mandarapharma

Cambridge, UK, 27th April 2021 – TRx announces completion of its first cannabinoid research partnership in with strain informatics specialist, Mandarapharma.

View Article

TRx Biosciences files Biodistribution Technology Platform IP

Cambridge, UK, 27th March 2021 – TRx’s proprietary technology platform represents a paradigm shift in the way that oral drug uptake is considered.

View Article

TRx signs Research Agreement with Oxilio Limited for OXL001

Cambridge, UK, 13th January 2021 – TRx announces completion of its first research partnership in oncology with drug repurposing pioneer, Oxilio Limited.

View Article

TRx Biosciences opens R&D facility at Babraham Campus, Cambridge

Cambridge, UK, 18th November 2020 – TRx commences development of its novel oral delivery platform, offering a step-change in drug biodistribution.

View Article